In the clinic, erlotinib has been combined with the non-ATP competitive pan Akt inhibitor MK-2206 in a phase II clinical trial enrolling advanced NSCLC patients with either mutant or wildtype EGFR49. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.